



Abgenix Extends Antibody Collaboration With Amgen

FREMONT, Calif. - January 9, 2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today that it has extended its research collaboration, option and license agreement with Amgen, Inc. (Amgen). Under the extended agreement, Abgenix will use its XenoMouseT technology to generate fully human monoclonal antibodies to antigen targets supplied by Amgen during the collaboration's five-year term.

As in the terms of the April 1999 agreement, Abgenix will receive research payments and could receive milestone and license payments, plus royalties on any future product sales by Amgen. Amgen will be responsible for product development, manufacturing, and commercialization of any products developed through the collaboration.

"We are pleased to expand existing relationships with our customers," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "This commitment by Amgen exemplifies the growing interest for antibody therapeutics among leading biotechnology companies."

"We are pleased to extend our relationship with Abgenix," said Amgen executive vice president and head of research, Dennis M. Fenton, Ph.D. "This extended agreement provides Amgen with access to Abgenix's fully human monoclonal antibody technology, which is a good strategic fit for our overall antibody strategy."

Abgenix is a biopharmaceutical company focused on the development and commercialization of antibody therapies for a variety of diseases. The company developed XenoMouseT technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix uses its XenoMouse technology to build a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products. For more information on Abgenix, visit the company's website at www.abgenix.com.

Statements made in this press release about Abgenix's XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

###